ANXA3 and triple-negative breast carcinoma: Similar findings were reported by research involving triple negative breast cancer cell lines MDA-MB-231 and MDA-MB-486, which found mesenchymal-epithelial transition (MET) in cancer cells receiving ANXA3-targetting shRNA plasmids, evidenced by decreased mesenchymal markers (vimentin and N-cadherin) and increased epithelial markers (E-cadherin and γ-cadherin) (Du et al., 2018).